ALPS Advisors’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

ALPS Advisors’s Portfolio MYOK Stock Details MYOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-70,988	Closed	-$4.63M	–	980
2018 Q3	$4.63M	Buy	70,988 +13,833	+24%	+$813K	0.03%	169
2018 Q2	$2.84M	Buy	57,155 +9,219	+19%	+$446K	0.02%	205
2018 Q1	$2.34M	Buy	47,936 +8,332	+21%	+$433K	0.02%	200
2017 Q4	$1.67M	Buy	39,604 +5,179	+15%	+$200K	0.01%	207
2017 Q3	$1.48M	Buy	34,425 +6,032	+21%	+$192K	0.01%	210
2017 Q2	$372K	Buy	+28,393	New	+$374K	﹤0.01%	695

Other funds holding MYOK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ALPS Advisors's MYOK Position: Q4 2018 in Review

ALPS Advisors sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2018, closing a stake of 70,988 shares — an estimated $4.63M sold.

ALPS Advisors first reported a position in MYOK in Q2 2017 and held it in 6 quarters. The position peaked at $4.63M in Q3 2018. 145 funds tracked by Wall St. Rank hold MYOK as of Q4 2018.

ALPS Advisors reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
ALPS Advisors sold 70,988 MyoKardia, Inc. Common Stock shares in Q4 2018, an estimated $4.63M.
ALPS Advisors first reported a position in MyoKardia, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
ALPS Advisors's MyoKardia, Inc. Common Stock position peaked at $4.63M in Q3 2018.
145 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.